Overview
Prior to my retirement from Duke with emeritus status, my clinical and research interests included systemic vasculitis (Granulomatosis with polyangiitis, microscopic polyangiitis, giant cell arteritis, Takayasu arteritis) and multi-disciplinary efforts in the areas of systemic lupus erythematosus and anti-phospholipid syndrome. Dr. E. William St. Clair and I represented Duke in both the RAVE trial, a multi-center, double-blind, controlled trial comparing rituximab with cyclophosphamide in patients with ANCA-associated vasculitis and previously the Wegener's granulomatosis etanercept trial (WGET), a multi-center effort to assess the addition of etanercept to traditional therapy in limited and severe forms of this type of vasculitis.
Current Appointments & Affiliations
Professor Emeritus of Medicine
·
2020 - Present
Medicine, Rheumatology and Immunology,
Medicine
Recent Publications
Saying Goodbye
Chapter · January 1, 2024 Goodbye: taking a leave; originally used in 1565-1575 AD as a contraction of “God be with ye”. ... Full text CiteHospital Admissions and Mortality in Patients With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Journal Article J Clin Rheumatol · September 1, 2023 BACKGROUND/OBJECTIVES: Anti-neutrophil cytoplasmic antibody-associated vasculitis has reported hospital mortality rates ranging between 10% and 20% with inadequate information regarding causes and outcomes of these hospitalizations. Characterization of out ... Full text Link to item CiteLong-Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis.
Journal Article Arthritis Care Res (Hoboken) · September 2021 OBJECTIVE: The present study was undertaken to conduct a phase IV, open-label, prospective study to characterize the long-term safety of rituximab in a 4-year observational registry of adult patients with granulomatosis with polyangiitis (GPA) or microscop ... Full text Link to item CiteEducation, Training & Certifications
Tufts University ·
1978
M.D.